Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus.

Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus. - GLSG, 2003, ADV

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000190

Enrollment

Registered

2005-09-12

Start date

2003-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B

Interventions

Adefovir dipivoxil 10mg/day p.o. for at least 48 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic hepatitis B Lamivudine-resistant mutants Abnormal ALT positive test of HBV-DNA

Exclusion criteria

Exclusion criteria: Allergy to lamivudine complication of chronic hepatitis C coadministration of cytotoxic drugs leucopenia during pregnancy severe liver dysfunction

Design outcomes

Primary

Measure	Time frame
HBV-DNA	—

Secondary

Measure	Time frame
Serum ALT side effects	—

Countries

Japan

Contacts

Public ContactKen Sato

Gunma University Graduate School of Medicine Department of Medicine and Molecular Science

satoken@showa.gunma-u.ac.jp027-220-8127

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026